Literature DB >> 27621569

Multisciplinary management of patients with liver metastasis from colorectal cancer.

Kathleen De Greef1, Christian Rolfo1, Antonio Russo1, Thiery Chapelle1, Giuseppe Bronte1, Francesco Passiglia1, Andreia Coelho1, Konstantinos Papadimitriou1, Marc Peeters1.   

Abstract

Colorectal cancer (CRC) is one of the leading causes of cancer-related death. Surgery, radiotherapy and chemotherapy have been till now the main therapeutic strategies for disease control and improvement of the overall survival. Twenty-five per cent (25%) of CRC patients have clinically detectable liver metastases at the initial diagnosis and approximately 50% develop liver metastases during their disease course. Twenty-thirty per cent (20%-30%) are CRC patients with metastases confined to the liver. Some years ago various studies showed a curative potential for liver metastases resection. For this reason some authors proposed the conversion of unresectable liver metastases to resectable to achieve cure. Since those results were published, a lot of regimens have been studied for resectability potential. Better results could be obtained by the combination of chemotherapy with targeted drugs, such as anti-VEGF and anti-EGFR monoclonal antibodies. However an accurate selection for patients to treat with these regimens and to operate for liver metastases is mandatory to reduce the risk of complications. A multidisciplinary team approach represents the best way for a proper patient management. The team needs to include surgeons, oncologists, diagnostic and interventional radiologists with expertise in hepatobiliary disease, molecular pathologists, and clinical nurse specialists. This review summarizes the most important findings on surgery and systemic treatment of CRC-related liver metastases.

Entities:  

Keywords:  Chemotherapy; Colorectal cancer; Liver metastases; Liver resection; Multidisciplinary team

Mesh:

Substances:

Year:  2016        PMID: 27621569      PMCID: PMC4997640          DOI: 10.3748/wjg.v22.i32.7215

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  116 in total

1.  Guidelines for resection of colorectal cancer liver metastases.

Authors:  O J Garden; M Rees; G J Poston; D Mirza; M Saunders; J Ledermann; J N Primrose; R W Parks
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

2.  Benefits and risks of neoadjuvant therapy for liver metastases.

Authors:  Bernard Nordlinger; Stéphane Benoist
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

3.  RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.

Authors:  Jean-Nicolas Vauthey; Giuseppe Zimmitti; Scott E Kopetz; Junichi Shindoh; Su S Chen; Andreas Andreou; Steven A Curley; Thomas A Aloia; Dipen M Maru
Journal:  Ann Surg       Date:  2013-10       Impact factor: 12.969

4.  Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution.

Authors:  Michael G House; Hiromichi Ito; Mithat Gönen; Yuman Fong; Peter J Allen; Ronald P DeMatteo; Murray F Brennan; Leslie H Blumgart; William R Jarnagin; Michael I D'Angelica
Journal:  J Am Coll Surg       Date:  2010-05       Impact factor: 6.113

5.  Repeated liver resection for recurrence of colorectal cancer metastases.

Authors:  Jaime Ruiz-Tovar; Pedro López Hervás
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

Review 6.  Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.

Authors:  D Zorzi; A Laurent; T M Pawlik; G Y Lauwers; J-N Vauthey; E K Abdalla
Journal:  Br J Surg       Date:  2007-03       Impact factor: 6.939

7.  Preoperative assessment of liver function: a comparison of 99mTc-Mebrofenin scintigraphy with indocyanine green clearance test.

Authors:  Deha Erdogan; Bob H M Heijnen; Roelof J Bennink; Mariël Kok; Sander Dinant; Irene H Straatsburg; Dirk J Gouma; Thomas M van Gulik
Journal:  Liver Int       Date:  2004-04       Impact factor: 5.828

Review 8.  [Recent advances in the case management of colorectal cancer liver metastases].

Authors:  Bernard Nordlinger; Stéphane Benoist
Journal:  Bull Acad Natl Med       Date:  2003       Impact factor: 0.144

9.  Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.

Authors:  C Garufi; A Torsello; S Tumolo; G M Ettorre; M Zeuli; C Campanella; G Vennarecci; M Mottolese; I Sperduti; F Cognetti
Journal:  Br J Cancer       Date:  2010-10-19       Impact factor: 7.640

10.  Factors influencing the natural history of colorectal liver metastases.

Authors:  R Stangl; A Altendorf-Hofmann; R M Charnley; J Scheele
Journal:  Lancet       Date:  1994-06-04       Impact factor: 79.321

View more
  26 in total

1.  Laparoscopic surgery for rectal cancer: the verdict is not final yet!

Authors:  Sherief Shawki; David Liska; Conor P Delaney
Journal:  Tech Coloproctol       Date:  2017-03-10       Impact factor: 3.781

Review 2.  A Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms.

Authors:  A S Khazali; A M Clark; A Wells
Journal:  Stem Cell Rev Rep       Date:  2017-06       Impact factor: 5.739

3.  Gene Expression in the Liver Remnant Is Significantly Affected by the Size of Partial Hepatectomy: An Experimental Rat Study.

Authors:  Michelle Meier; Anders Riegels Knudsen; Kasper Jarlhelt Andersen; Niels Christian Bjerregaard; Uffe Birk Jensen; Frank Viborg Mortensen
Journal:  Gene Expr       Date:  2017-05-09

Review 4.  Intraoperative Ultrasound as a Screening Modality for the Detection of Liver Metastases during Resection of Primary Colorectal Cancer - A Systematic Review.

Authors:  Signe Bremholm Ellebæk; Claus Wilki Fristrup; Michael Bau Mortensen
Journal:  Ultrasound Int Open       Date:  2017-06-07

5.  Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases.

Authors:  Andrew Kennedy; Michael Cohn; Douglas M Coldwell; Alain Drooz; Eduardo Ehrenwald; Adeel Kaiser; Charles W Nutting; Steven C Rose; Eric A Wang; Michael A Savin
Journal:  J Gastrointest Oncol       Date:  2017-08

6.  The Effect of Multidisciplinary Team Discussion Intervention on the Prognosis of Advanced Colorectal Cancer.

Authors:  Huaqi Zhang; Jishang Yu; Zhewei Wei; Wenhui Wu; Changhua Zhang; Yulong He
Journal:  J Cancer       Date:  2021-04-07       Impact factor: 4.207

7.  miR-181d and c-myc-mediated inhibition of CRY2 and FBXL3 reprograms metabolism in colorectal cancer.

Authors:  Xiaofeng Guo; Yuekun Zhu; Xinya Hong; Mukun Zhang; Xingfeng Qiu; Zhenfa Wang; Zhongquan Qi; Xuehui Hong
Journal:  Cell Death Dis       Date:  2017-07-27       Impact factor: 8.469

Review 8.  Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer.

Authors:  Chiara Guarini; Teresa Grassi; Gaetano Pezzicoli; Camillo Porta
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

9.  Identification of dysregulated lncRNAs profiling and metastasis-associated lncRNAs in colorectal cancer by genome-wide analysis.

Authors:  Yan Chen; Xiang Yu; Yongcan Xu; Hua Shen
Journal:  Cancer Med       Date:  2017-08-31       Impact factor: 4.452

10.  Silencing Lin28 promotes apoptosis in colorectal cancer cells by upregulating let‑7c targeting of antiapoptotic BCL2L1.

Authors:  Haogang Zhang; Yaguang Zong; Gongcai Qiu; Ruichun Jia; Xunzheng Xu; Fujing Wang; Dequan Wu
Journal:  Mol Med Rep       Date:  2018-01-25       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.